Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a $17.00 price objective on the stock.

Several other research analysts have also commented on IMUX. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Trading Up 1.7 %

Immunic stock opened at $1.17 on Wednesday. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The stock has a market cap of $105.39 million, a P/E ratio of -0.95 and a beta of 1.87. The stock has a 50 day moving average of $1.03 and a 200-day moving average of $1.25.

Institutional Investors Weigh In On Immunic

Several hedge funds have recently modified their holdings of IMUX. Focus Partners Wealth boosted its stake in Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares in the last quarter. 683 Capital Management LLC raised its position in shares of Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after acquiring an additional 15,349 shares during the last quarter. Millennium Management LLC boosted its stake in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after buying an additional 177,542 shares during the period. Finally, Bridgeway Capital Management LLC raised its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares during the period. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.